Skip to content

Schering-Plough SGP Other Income (Expense)

Other Income (Expense) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$188.3M-39.9%
Glaukos logo
GlaukosGKOS
$557K-80.5%
Bausch + Lomb logo
Bausch + LombBLCO
-$3M+50.0%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$2.34M-35.6%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$4.73M+3,576%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
-$29K+79.1%

Other financials

Income statement

See full
Operating income-$15.4M-108%
Net income-$13.8M-56.6%
EPS (diluted)-$0.69+82.6%

Balance sheet

See full
Cash & equivalents$238.9M+312%
Total debt$1.6M
Total equity$250.1M+463%
Total assets$258.4M

Cash flow

See full
Operating cash flow-$13.5M-65.2%
CapEx$676.0K+312%
Free cash flow-$14.2M-70.0%

Valuation

See full
Market cap$744.23M-23.4%
Enterprise value$506.93M

Returns & leverage

See full
Return on equity-34.3%
Debt / equity
Current ratio38×

Where this comes from

Reported directly by Schering-Plough in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The official record: Schering-Plough’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schering-Plough's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schering-Plough's other income (expense)?
Schering-Plough (SGP) reported other income (expense) of $1.59M in Q1 2026.
How has Schering-Plough's other income (expense) changed year-over-year?
Schering-Plough's other income (expense) increased by 213.6% year-over-year, from -$1.4M to $1.59M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.